Incyte EVP Mayes granted 4,218 stock options
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026.
Rhea-AI Filing Summary
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 4,218 | $0.00 | $0.00 |
Footnotes (1)
- F1. Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.
FAQ
What insider transaction did INCYTE CORP (INCY) report for Patrick A. Mayes?
What is the exercise price of Patrick A. Mayes’s new Incyte (INCY) stock options?
How do the newly granted INCY stock options vest for Patrick A. Mayes?
When do Patrick A. Mayes’s Incyte (INCY) stock options expire?
How many Incyte derivative securities does Patrick A. Mayes own after this Form 4 transaction?
What role does Patrick A. Mayes hold at Incyte (INCY)?
AI-generated analysis. How Rhea-AI works. Not financial advice.